Originally developed to treat diabetes, a class of drugs known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are ...

Combining GLP-1 agonists with progestins lowered endometrial cancer risk by 66% compared to progestins alone. The GLP-1 agonist/progestin combination outperformed metformin/progestins in reducing ...

Orforglipron, a small-molecule, nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, is being investigated as a treatment for obesity. In this phase 3, multinational, randomized, ...

—Study findings highlight the need for improved recommendations of guideline-directed therapies and support the consideration of dual therapy in appropriately selected high-risk patients. In a study ...

Please provide your email address to receive an email when new articles are posted on . A link was found between GLP-1 receptor agonist use in PAH and significant decreases in mortality, respiratory ...

GLP-1 receptor agonists are linked to a 55% reduction in mortality risk in women with ovarian cancer, based on a retrospective cohort study. The study utilized data from the TriNetX Research Network, ...